Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 25 , ISSUE 4 ( April, 2021 ) > List of Articles

EDITORIAL

A Shot in the Dark! RAAS Inhibitors Cause Severe COVID-19 Infection

Bhuvana Krishna

Citation Information : Krishna B. A Shot in the Dark! RAAS Inhibitors Cause Severe COVID-19 Infection. Indian J Crit Care Med 2021; 25 (4):353-354.

DOI: 10.5005/jp-journals-10071-23796

License: CC BY-NC 4.0

Published Online: 00-04-2021

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract


PDF Share
  1. World Health Organization. COVID-19 weekly epidemiological update, 2 February 2021.
  2. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(2):271–280. DOI: 10.1016/j.cell.2020.02.052.
  3. Tikellis C, Thomas MC. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin-angiotensin system in health and disease. Int J Pept 2012;2012:256294. DOI: 10.1155/2012/256294.
  4. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005;111(20):2605–2610. DOI: 10.1161/CIRCULATIONAHA.104.510461.
  5. Sriram K, Insel PA. Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence. Clin Pharmacol 2020;108(2):236–241. DOI: 10.1002/cpt.1863.
  6. Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180(7):934–943. DOI: 10.1001/jamainternmed.2020.0994.
  7. Wang JJ, Edin ML, Zeldin DC, Li C, Wang DW, Chen C. Good or bad: application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities. Pharmacol Ther 2020;215:107628. DOI: 10.1016/j.pharmthera.2020.107628.
  8. Grover A, Oberoi M. A systematic review to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. MedRxiv 2020. DOI: 10.1101/2020.04.29.20085787.
  9. Mackey K, King VJ, Gurley S, Kiefer M, Liederbauer E, Vela K, et al. Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults: a living systematic review. Ann Intern Med 2020;173(3):195–203. DOI: 10.7326/M20-1515.
  10. Kurdi A, Abutheraa N, Akil L, Godman B. A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: what is the evidence so far? Pharmacol Res Perspect 2020;8(6):e00666. DOI: 10.1002/prp2.666.
  11. Reddy PR, Samavedam S, Aluru N, Rajyalakshmi B. Comparison of severity of COVID-19 infection among patients using RAAS inhibitors and non-RAAS inhibitors. Indian J Crit Care Med 2021;25(4):366–368.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.